Print Version
MMWR: Fatal and Severe Hepatitis Associated with Rifampin and Pyrazinamide for the Treatment of Latent Tuberculosis Infection--New York and Georgia, 2000
Author:
Centers for Disease Control and Prevention (CDC), US Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention (CDC), National Center for Health Statistics, Office of the Morbidity and Mortality Weekly Report Series, CDC MMWR
Publication Date:
2001
Country of Origin:
United States
Format:
Report
Language:
English
Abstract
This report discusses two cases of latent TB infection in which patients developed severe or fatal hepatitis associated with rifampin-pyrazinamide (RIF-PZA) treatment.Publisher:
Centers for Disease Control and Prevention (CDC)
Audience(s):
Health Professionals
Topic:
Treatment- Adverse Reactions, Treatment - Latent TB infection (Inactive TB), TB Treatment, Treatment- Medication Information
Notes:
Massachusetts Medical Society: paper copies of single issues cost $5.25.
Disclaimer: The information on the Find TB Resources Website is made available as a public service. Neither the Centers for Disease Control and Prevention nor the National Prevention Information Network endorses the organizations, Website s, and materials presented. It is the responsibility of the user to evaluate this information prior to use based on individual, community, and organizational needs and standards.